Department of Clinical Hematology, King George's Medical University, Lucknow, Pin-22603, India.
Department of Clinical Hematology, King George's Medical University, Lucknow, Pin-22603, India.
Indian J Tuberc. 2021 Jul;68(3):412-415. doi: 10.1016/j.ijtb.2020.11.004. Epub 2020 Nov 7.
Current standard of care for treatment of CML is based on tyrosine kinase inhibitors (TKI's). Imatinib is most frequently used first line tyrosine kinase inhibitor. Various side effects of TKI's are known, but some may still be unknown. We are reporting three cases of CML who developed tuberculosis while on treatment with imatinib or dasatinib. Two cases developed CNS tuberculosis and other one was tubercular pleural effusion. These cases indicate that imatinib and other TKI's probably interfere with immunological functions and predispose patients for tuberculosis.
目前治疗 CML 的标准治疗方法基于酪氨酸激酶抑制剂（TKI）。伊马替尼是最常用的一线酪氨酸激酶抑制剂。已知 TKI 有各种副作用，但有些可能仍未知。我们报告了三例在接受伊马替尼或达沙替尼治疗时发生结核病的 CML 患者。其中两例发生中枢神经系统结核，另一例为结核性胸腔积液。这些病例表明，伊马替尼和其他 TKI 可能会干扰免疫功能，使患者易患结核病。
